Which stock is this? Let's see if people remember pre covid. Hint in next comment

Good stuff here for folks new to biotech investing: adus.substack.com/p/biotech-an... by @plainyogurt21.bsky.social

American College of Cardiology (ACC) 2025 is < 2 weeks away.

I've indexed all 4600+ abstracts with tagged by trial ID, drug, conditions, type of study, and summaries,

email me at [email protected] for the excel grouped by session.

If I had to pick three things to learn about biotech investing in <3 hours

microcapclub.com/microcap-lif...

lifescivc.com/2024/04/deco...

www.pharmagellan.com/blog/clinica...

AI for Research: A Practical Guide for Analysts open.substack.com/pub/adus/p/1...
AI will change white collar work: but no one is discussing actually useful examples.

Some practical uses for AI all for < 50$/month. Tailored to biotech

adus.substack.com/p/how-does-r...

new post up

Detailed FDA analysis by @plainyogurt21.bsky.social with many case studies — recommended! (Bookmarking for my drug dev course this spring.) adus.substack.com/p/fda-and-re...

H/T to one of the BioTwitter goats @biotechElmo.

This is what ChatGPT says is the impact and thoughts on marty makary ( I asked to source based on pre September 2024 to avoid recent articles).
All of it is a bit vague but makes sense. Overall, His focus is likely on large companies and transparency.

$BBIO, Everyone on their toes for the last few hours, Label looks clean with mortality benefit. Now up to execution. Expecting > 30% first line share. Patent issues will weigh on it. Important to note the royalties received on FDA approval to alleviate the cash situation

Really good list from @franksdavid.bsky.social . I think refreshing the basics and looking back on history through some of the books he mentioned is helpful for everyone. Pairs well with my list of biotech investors resources compiled here: x.com/plainyogurt2...

blue sky feels more like the early internet. There might be something here but until it hits a critical mass, I’m gonna see random posts in my feed. The amount of content is simple not enough to maintain a large feed imo….yet

I recently did a post with my takeaways from #AHA24 with relevant updates on ATTR-Cardiomyopathy (TTR silencing, editing, and Acoramidis, Danon Disease with Rocket Pharmaceuticals and an under the radar abstract from Tectonic therapeutics.
adus.substack.com/p/quick-take...